



bRIGHT
S T U D Y

REAL-WORLD REGISTRY

TriClip™

Transcatheter
Edge-to-Edge Repair

“

We see very **short learning curves** and the ability to adopt the therapy **safely and effectively**. We see a **great safety profile** and confirm the previous effectiveness results of the TRILUMINATE trial. ... It's confirmed looking at much more centers and **reflecting real-world practice**.”

Prof. Dr. Philipp Lurz

bRIGHT Principal Investigator

bRIGHT STUDY 1-YEAR DATA¹

Objective

Evaluating the safety and effectiveness of TriClip™ TEER in patients with severe TR in a real-world, post-market setting.

Study Design

Prospective, single-arm, multicenter registry (minimum 500 subjects at approximately 30 sites in Europe).



Mean Age
78
± 8 Years



NYHA
81%
Functional Class III/IV


Studied in an elderly, fragile, real-world patient population



Scan to learn more about
TriClip™ TEER



TR GRADE (CORE LAB)¹



Information contained herein for **DISTRIBUTION outside of the U.S. ONLY**.
Always check the regulatory status for the device in your region.

PROVEN IN THE LARGEST BODY OF REAL-WORLD EVIDENCE TO DATE^{1,2}

bRIGHT Study 30-day Procedural Data³

High rates of success across diverse patient anatomies



2.5–7.6 cm
RANGE OF ANNULAR
DIAMETERS



2.6–20.8 mm
MEASURED GAP
SIZES



21%
OF PATIENTS WITH
> 3 LEAFLETS



19%
OF PATIENTS HAD A
PACEMAKER LEAD

High Procedural Success

98% implant
success rate

Short Device Time

78 average device
time (minutes)
± 41

High Safety Profile at 30 Days



99% freedom
from MAEs

99.7% survival

0.3% nonelective CV surgery,
TVRS device-related AE

0% embolization

bRIGHT Study Life-changing Outcomes at 1-year¹



21
POINTS

significant improvement
in KCCQ-OS health-related
quality of life

AE = adverse event
CV = cardiovascular
MAE = major adverse event
NYHA = New York Heart Association
TEER = transcatheter edge-to-edge repair
TR = tricuspid regurgitation
KCCQ-OS = Kansas City Cardiomyopathy
Questionnaire Overall Summary Score

- Lurz P, Schmitz T, Bekeredjian R, et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 1 Year Outcomes from the bRIGHT trial. Presented at PCR London Valves; November 27-29, 2022; London, England.
- ClinicalTrials.gov. Find a Study. Accessed November 12, 2021. <https://clinicaltrials.gov/ct2/results?cond=tricuspid+regurgitation&term=transcatheter&cntry=&state=&city=&dist=>
- Lurz P, Lapp H, Schueler R, et al. Real-world Outcomes for Tricuspid Edge-to-Edge Repair: Initial 30-Day Results from the TriClip™ bRIGHT Study. Presented at: EuroPCR; May 17-18, 2022; Paris, France.

The testimonial does not provide any indication, guide, warranty or guarantee as to the response patients may have to the treatment or effectiveness of the product or therapy in discussion. Opinions about the treatment discussed can and do vary and are specific to the individual's experience and might not be representative of others.

CAUTION: This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Information contained herein for **DISTRIBUTION outside of the U.S. ONLY**. Always check the regulatory status for the device in your region.

Abbott
3200 Lakeside Dr., Santa Clara, CA. 95054 USA

™ Indicates a trademark of the Abbott group of companies.

‡ Indicates a third party trademark, which is property of its respective owner.
www.structuralheartsolutions.com

© 2022 Abbott. All Rights Reserved. | MAT-2115505 v3.0 | Item approved for Global OUS use only.

